Obesity is a chronic, relapsing disease with significant health and economic impacts. As obesity rates and new medication options rise, national societies have developed guidelines for high-quality pharmacologic care.
AGA has introduced new quality indicators to define and benchmark best practices for the use of obesity medications. These indicators are supported by strong evidence, address care gaps, and may be submitted for inclusion in national quality payment programs.